Plain-English translation of NCT07036003 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This clinical trial is testing whether Saizen Somatropin (a recombinant human growth hormone) can help people with knee osteoarthritis feel better and move more easily. Half of the participants will receive the active medication, and half will receive a placebo (a harmless salt solution), so researchers can see if the medication actually works. The study lasts 6 weeks and involves daily self-injections.
Knee osteoarthritis causes pain and loss of function that can really affect quality of life, and current treatments don't work well for everyone. This trial is exploring whether this medication might help regenerate or protect the knee joint and offer relief to people who haven't had success with other options.
You will give yourself one injection per day for 6 weeks, either in your abdomen or buttock area. During this time, you'll complete questionnaires about your knee pain and daily activities, have your blood drawn, and undergo measurements including thigh and knee strength, range of motion, and walking analysis. The study will help researchers understand whether this medication is safe and whether people can stick with the daily injection routine.
AI-generated summary from trial data · Aug 14, 2026 · Not medical advice
Canada